Armin Mooranian1, Rebecca Negrulj1, Ryu Takechi2, Emma Jamieson3, Grant Morahan3, Hani Al-Salami1. 1. Biotechnology & Drug Development Research Laboratory, School of Pharmacy, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia. 2. School of Public Health, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia. 3. Harry Perkins Institute of Medical Research, Centre for Diabetes Research, Perth, Western Australia, Australia.
Abstract
AIM: A semisynthetic primary bile acid (PBA) has exerted hypoglycemic effects in Type 1 diabetic animals, which were hypothesized to be due to its anti-inflammatory and cellular glucose-regulatory effects. Thus, the research purpose aimed to examine antidiabetic effects of a PBA, in terms of cellular inflammation and survival and insulin release, in the context of supporting β-cell delivery and Type 1 diabetic treatment. MATERIALS & METHODS: 10 formulations were prepared, five without PBA (control) and five with PBA (test). Formulations were used to microencapsulate pancreatic β cells and the microcapsules were examined for morphology, cell viability, insulin release and inflammation. RESULTS & CONCLUSION: PBA improved cell viability, insulin release and reduced inflammation in a formulation-dependent manner, which suggests potential use in cell delivery and diabetes treatment. [Formula: see text].
AIM: A semisynthetic primary bile acid (PBA) has exerted hypoglycemic effects in Type 1 diabetic animals, which were hypothesized to be due to its anti-inflammatory and cellular glucose-regulatory effects. Thus, the research purpose aimed to examine antidiabetic effects of a PBA, in terms of cellular inflammation and survival and insulin release, in the context of supporting β-cell delivery and Type 1 diabetic treatment. MATERIALS & METHODS: 10 formulations were prepared, five without PBA (control) and five with PBA (test). Formulations were used to microencapsulate pancreatic β cells and the microcapsules were examined for morphology, cell viability, insulin release and inflammation. RESULTS & CONCLUSION:PBA improved cell viability, insulin release and reduced inflammation in a formulation-dependent manner, which suggests potential use in cell delivery and diabetes treatment. [Formula: see text].
Entities:
Keywords:
artificial cell microencapsulation; bile acid; pancreatic β cells
Authors: Armin Mooranian; Thomas Foster; Corina M Ionescu; Louise Carey; Daniel Walker; Melissa Jones; Susbin Raj Wagle; Bozica Kovacevic; Jacqueline Chester; Edan Johnstone; Jafri Kuthubutheen; Daniel Brown; Marcus D Atlas; Momir Mikov; Hani Al-Salami Journal: Drug Des Devel Ther Date: 2021-10-23 Impact factor: 4.162